In a separate trial, Fassnacht et al66 conducted a phase III trial involving linsitinib, an inhibitor targeting both IGF-1R and the insulin receptor, compared to a placebo in patients with locally advanced or metastatic ACC. Here, IGF1R is linked to adrenal cortex carcinoma.